Gilead to Offer Senior Notes
March 23 2011 - 9:12AM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced its
intention to offer, subject to market and other conditions, senior
notes under a shelf registration statement on file with the
Securities and Exchange Commission. The interest rate, the maturity
dates and other key terms of the offering are to be determined at
the time of pricing.
Gilead intends to use the net proceeds from this offering for
general corporate purposes, which may include the repayment of
certain indebtedness and the repurchase of outstanding common stock
pursuant to the company’s authorized share repurchase program.
Bank of America Merrill Lynch, J.P. Morgan and Morgan Stanley
are acting as joint book-running managers for the offering. The
offering of the securities is being made only by means of a
prospectus supplement and the accompanying base prospectus, which
is part of Gilead’s effective shelf registration statement filed
with the Securities and Exchange Commission, copies of which may be
obtained from:
Bank of America
SecuritiesLLC
J. P. Morgan Securities LLC
Morgan Stanley &
Co.Incorporated
Prospectus Department
383 Madison Avenue
180 Varick Street
100 West 33rd Street
New York, NY 10179
New York, NY 10014
New York, NY 10001
Attention: Investment GradeSyndicate
Desk
Attention: ProspectusDepartment
800 294 1322
212 834 4533
866 718 1649
Before you invest, you should read the prospectus supplement and
the accompanying base prospectus in Gilead’s effective registration
statement and other documents Gilead has filed with the Securities
and Exchange Commission for more complete information about Gilead
and this offering. You may get these documents for free by visiting
the Securities and Exchange Commission’s website at
www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company's mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific.
Forward-Looking
Statement
This press release includes forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of
1995, that are subject to risks, uncertainties and other factors,
including the current market demand for these types of securities
and the securities of Gilead and the negotiations between Gilead
and the underwriters. These risks, uncertainties and other factors
could cause actual results to differ materially from those referred
to in the forward-looking statements. The reader is cautioned not
to rely on these forward-looking statements. Other risks that could
impact the offering are described in detail in Gilead's Annual
Report on Form 10-K for the year ended December 31, 2010 as filed
with the U.S. Securities and Exchange Commission, and may be
updated by the risk factors set forth in any subsequent filing by
Gilead with the U.S. Securities and Exchange Commission. All
forward-looking statements are based on information currently
available to Gilead and Gilead assumes no obligation to update any
such forward-looking statements.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024